> top > docs > PMC:7324763 > spans > 80281-81494 > annotations

PMC:7324763 / 80281-81494 JSONTXT

Annnotations TAB JSON ListView MergeView

LitCovid-PMC-OGER-BB

Id Subject Object Predicate Lexical cue
T1288 24-30 UBERON:0002405;GO:0006955 denotes immune
T1289 31-41 GO:0006955 denotes modulating
T1290 81-89 SP_7 denotes COVID-19
T1291 174-185 NCBITaxon:1 denotes individuals
T1292 429-440 NCBITaxon:1 denotes Individuals
T1293 470-478 SP_7 denotes COVID-19
T1294 589-595 UBERON:0002405 denotes immune
T1295 819-827 SP_7 denotes COVID-19
T1296 962-979 CHEBI:35705;CHEBI:35705 denotes immunosuppressive
T1297 1068-1074 UBERON:0002405 denotes immune
T1298 1116-1125 CHEBI:21241;CHEBI:21241 denotes vitamin C
T1299 1130-1139 CHEBI:27300;CHEBI:27300 denotes vitamin D
T1300 1195-1203 SP_7 denotes COVID-19
T78105 24-30 UBERON:0002405;GO:0006955 denotes immune
T77112 31-41 GO:0006955 denotes modulating
T97273 81-89 SP_7 denotes COVID-19
T54596 174-185 NCBITaxon:1 denotes individuals
T6473 429-440 NCBITaxon:1 denotes Individuals
T17163 470-478 SP_7 denotes COVID-19
T17141 589-595 UBERON:0002405 denotes immune
T47170 819-827 SP_7 denotes COVID-19
T91081 962-979 CHEBI:35705;CHEBI:35705 denotes immunosuppressive
T91334 1068-1074 UBERON:0002405 denotes immune
T9380 1116-1125 CHEBI:21241;CHEBI:21241 denotes vitamin C
T99008 1130-1139 CHEBI:27300;CHEBI:27300 denotes vitamin D
T12216 1195-1203 SP_7 denotes COVID-19

LitCovid-PD-FMA-UBERON

Id Subject Object Predicate Lexical cue fma_id
T906 629-636 Body_part denotes NK cell http://purl.org/sig/ont/fma/fma63147
T907 632-636 Body_part denotes cell http://purl.org/sig/ont/fma/fma68646

LitCovid-PD-MONDO

Id Subject Object Predicate Lexical cue mondo_id
T561 81-89 Disease denotes COVID-19 http://purl.obolibrary.org/obo/MONDO_0100096
T562 470-478 Disease denotes COVID-19 http://purl.obolibrary.org/obo/MONDO_0100096
T563 819-827 Disease denotes COVID-19 http://purl.obolibrary.org/obo/MONDO_0100096
T564 1195-1203 Disease denotes COVID-19 http://purl.obolibrary.org/obo/MONDO_0100096

LitCovid-PD-CLO

Id Subject Object Predicate Lexical cue
T946 151-152 http://purl.obolibrary.org/obo/CLO_0001020 denotes A
T947 198-199 http://purl.obolibrary.org/obo/CLO_0001020 denotes a
T948 426-427 http://purl.obolibrary.org/obo/CLO_0001021 denotes B
T949 450-456 http://purl.obolibrary.org/obo/UBERON_0000473 denotes tested
T950 629-636 http://purl.obolibrary.org/obo/CL_0000623 denotes NK cell

LitCovid-PD-CHEBI

Id Subject Object Predicate Lexical cue chebi_id
T903 1116-1125 Chemical denotes vitamin C http://purl.obolibrary.org/obo/CHEBI_21241
T212 1116-1123 Chemical denotes vitamin http://purl.obolibrary.org/obo/CHEBI_33229
T213 1130-1139 Chemical denotes vitamin D http://purl.obolibrary.org/obo/CHEBI_27300
T56457 1130-1137 Chemical denotes vitamin http://purl.obolibrary.org/obo/CHEBI_33229

LitCovid-PubTator

Id Subject Object Predicate Lexical cue tao:has_database_id
2233 90-98 Species denotes patients Tax:9606
2234 828-836 Species denotes patients Tax:9606
2235 1204-1212 Species denotes patients Tax:9606
2236 1116-1125 Chemical denotes vitamin C MESH:D001205
2237 1130-1139 Chemical denotes vitamin D MESH:D014807
2238 81-89 Disease denotes COVID-19 MESH:C000657245
2239 222-230 Disease denotes infected MESH:D007239
2240 470-478 Disease denotes COVID-19 MESH:C000657245
2241 819-827 Disease denotes COVID-19 MESH:C000657245
2242 1026-1034 Disease denotes toxicity MESH:D064420
2243 1195-1203 Disease denotes COVID-19 MESH:C000657245

LitCovid-sentences

Id Subject Object Predicate Lexical cue
T486 0-653 Sentence denotes Figure 2 Short-list of immune modulating therapies undergoing clinical trial in COVID-19 patients and recommendations on who should receive therapy. (A) Healthy, uninfected individuals, who are at a high risk of becoming infected (through situational circumstances such as healthcare workers) would be most fit and suitable to receive investigational prophylactic therapies such as exogenous IFNs and heterologous vaccines. (B) Individuals who have tested positive for COVID-19 that are asymptomatic or have mild to moderate disease progression may benefit from receiving investigational immune stimulating therapies, including NK cell-based therapies.
T487 654-990 Sentence denotes It is critical that investigators must be vigilant to assess the safety profile and potential immunopathologies associated with these immunotherapies. (C) In severe COVID-19 patients, the most appropriate therapies to investigate would be those that mitigate immunopathologies, such as anti-inflammatory and immunosuppressive therapies.
T488 991-1213 Sentence denotes Given the relatively low chance of toxicity and the wide range of beneficial immune effects, natural health products such as vitamin C and vitamin D can be suitable for investigation at all categories of COVID-19 patients.